European Academy of Tumor Immunology

The principal objective of the European Academy of Tumor Immunology (EATI) is to promote tumor immunology at the scientific and clinical levels.

european academy of tumor immunology
The principal objective of the European Academy of Tumor Immunology (EATI) is to promote tumor immunology at the scientific and clinical levels. EATI promotes all areas of tumor immunology, considered as a continuum between fundamental, translational and clinical research, as well as the practical implementation of diagnostic and therapeutic procedures in routi

ne clinical practice. EATI strives for excellence, independence, leadership, diversity and flexibility. Throughout its work, EATI provides independent, authoritative and evidence-based advice to underpin policy for stimulating the implementation of concepts, methods and procedures inspired by tumor immunology. The foundation of EATI was possible thanks to a generous grant, the “LabEx” Immuno-Oncology, provided by the “Grand Emprunt” of the French Republic. eati.academy
EATI serves as an instrument to crystallize and streamline all efforts in the European Research Area. The Founding Members of EATI have been selected among highly renowned scientists from all areas of tumor immunology. The Founding Group is responsible for defining the overall objectives of the Academy, addressing issues such as credibility of the institution, membership and governance. To steer the process, a ' Governing Body' consisting of a President, a Vice-President, a Secretary-General and several fellows representing all disciplines of tumor immunology Europe-wide, has been established. To address issues as they arise, ad hoc taskforces are organized amongst members of the Academy, specific to their area of expertise. As a Member of EATI you can anticipate contributing to the preparation of position papers, interacting with EU and national institutions to facilitate proposals and the implementation of new policies that ensure that disease-oriented systems biology remain at the top of the European research agenda. EATI was officially launched at the opening of the Euroconference on "Death, Danger, Immunity and Inflammation" at the Pasteur Institute, in Paris, in May 2011, the first annual conference of eati.

Photos from European Academy of Tumor Immunology's post

22/12/2023

25/09/2019

CICON19! Grand opening. 1500 people in the audience. What an amazing event

24/09/2019

Getting ready for the CICON. See you all tomorrow!

23/06/2019

CICON 2019 in Paris

27/11/2018

2019 International Cancer Immunotherapy Conference The Fifth CRI-CIMT-EATI-AACR CICON takes place September 25-28, 2019, at Espace Grand Arche de la Défense in Paris, France.

03/10/2018

Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference Press Briefing

03/10/2018

BREAKING NEWS
The Nobel Assembly at Karolinska Institutet has today decided to award the 2018 Nobel Prize in Physiology or Medicine jointly to James P. Allison and Tasuku Honjo “for their discovery of cancer therapy by inhibition of negative immune regulation.”

Cancer kills millions of people every year and is one of humanity’s greatest health challenges. By stimulating the inherent ability of our immune system to attack tumour cells this year’s Nobel Laureates have established an entirely new principle for cancer therapy.

James P. Allison studied a known protein that functions as a brake on the immune system. He realised the potential of releasing the brake and thereby unleashing our immune cells to attack tumours. He then developed this concept into a brand new approach for treating patients.

In parallel, Tasuku Honjo discovered a protein on immune cells and, after careful exploration of its function, eventually revealed that it also operates as a brake, but with a different mechanism of action. Therapies based on his discovery proved to be strikingly effective in the fight against cancer.

Allison and Honjo showed how different strategies for inhibiting the brakes on the immune system can be used in the treatment of cancer. The seminal discoveries by the two laureates constitute a landmark in our fight against cancer.

Learn more: https://bit.ly/2OpzIIS